Circulating Level of Fibroblast Growth Factor 21 is Independently Associated with the Risks of Unstable Angina Pectoris

Overview

Journal Biosci Rep

Specialty Cell Biology

Date 2018 Sep 7

PMID 30185439

Citations 10

Authors

Jing Cheng

Xing Su

Lei Qiao

Chungang Zhai

Wenqiang Chen

Affiliations

Soon will be listed here.

Abstract

There is increasing evidence that serum adipokine levels are associated with higher risks of cardiovascular diseases. As an important adipokine, fibroblast growth factor 21 (FGF21) has been demonstrated to be associated with atherosclerosis and coronary artery disease (CAD). However, circulating level of FGF21 in patients with angina pectoris has not yet been investigated. Circulating FGF21 level was examined in 197 patients with stable angina pectoris (SAP, =66), unstable angina pectoris (UAP, =76), and control subjects (=55) along with clinical variables of cardiovascular risk factors. Serum FGF21 concentrations on admission were significantly increased more in patients with UAP than those with SAP (Ln-FGF21: 5.26 ± 0.87 compared with 4.85 ± 0.77, <0.05) and control subjects (natural logarithm (Ln)-FGF21: 5.26 ± 0.87 compared with 4.54 ± 0.72, <0.01). The correlation analysis revealed that serum FGF21 concentration was positively correlated with the levels of cardiac troponin I (cTnI) (r = 0.026, =0.027) and creatine kinase-MB (CK-MB) (r = 0.023, = 0.04). Furthermore, FGF21 level was identified as an independent factor associated with the risks of UAP (odds ratio (OR): 2.781; 95% CI: 1.476-5.239; 0.002), after adjusting for gender, age, and body mass index (BMI). However, there were no correlations between serum FGF21 levels and the presence of SAP (OR: 1.248; 95% CI: 0.703-2.215; 0.448). The present study indicates that FGF21 has a strong correlation and precise predictability for increased risks of UAP, that is independent of traditional risk factors of angina pectoris.

Citing Articles

Can Exercise-Mediated Adipose Browning Provide an Alternative Explanation for the Obesity Paradox?.

Zhao J, Li X, Liang C, Yan Y Int J Mol Sci. 2025; 26(5).

PMID: 40076419 PMC: 11898606. DOI: 10.3390/ijms26051790.

Connecting the Dots: FGF21 as a Potential Link between Obesity and Cardiovascular Health in Acute Coronary Syndrome Patients.

Negroiu C, Riza A, Streata I, Tudorascu I, Bezna C, Ungureanu A Curr Issues Mol Biol. 2024; 46(8):8512-8525.

PMID: 39194718 PMC: 11353113. DOI: 10.3390/cimb46080501.

The Correlation Between Serum Fibroblast Growth Factor 21 and the Severity and Occurrence of Coronary Artery Disease.

Sinha S, Prakash P, Keshari J, Prasad R Cureus. 2024; 16(1):e51924.

PMID: 38333506 PMC: 10851179. DOI: 10.7759/cureus.51924.

Elevated serum FGF21 is an independent predictor for adverse events in hemodialysis patients from two large centers: a prospective cohort study.

Li M, Jiang L, Zhang M, Liu S, Sawh R, Zheng J Ren Fail. 2023; 45(2):2256414.

PMID: 37724523 PMC: 10512844. DOI: 10.1080/0886022X.2023.2256414.

Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine.

Tan H, Yue T, Chen Z, Wu W, Xu S, Weng J Int J Biol Sci. 2023; 19(1):66-88.

PMID: 36594101 PMC: 9760446. DOI: 10.7150/ijbs.73936.

References

Patel V, Adya R, Chen J, Ramanjaneya M, Bari M, Bhudia S . Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts. PLoS One. 2014; 9(2):e87102. PMC: 3911936. DOI: 10.1371/journal.pone.0087102. View

Yan H, Xia M, Chang X, Xu Q, Bian H, Zeng M . Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study. PLoS One. 2011; 6(9):e24895. PMC: 3174975. DOI: 10.1371/journal.pone.0024895. View

Cheng X, Zhu B, Jiang F, Fan H . Serum FGF-21 levels in type 2 diabetic patients. Endocr Res. 2011; 36(4):142-8. DOI: 10.3109/07435800.2011.558550. View

Stefan N, Haring H . The role of hepatokines in metabolism. Nat Rev Endocrinol. 2013; 9(3):144-52. DOI: 10.1038/nrendo.2012.258. View

Wang J, Sheu W, Lee W, Lee I, Lin S, Lee W . Associations of fibroblast growth factor 21 with cardiovascular risk and β-cell function in patients who had no history of diabetes. Clin Chim Acta. 2017; 472:80-85. DOI: 10.1016/j.cca.2017.07.017. View

Wong N . Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol. 2014; 11(5):276-89. DOI: 10.1038/nrcardio.2014.26. View

Liu S, Roberts D, Kharitonenkov A, Zhang B, Hanson S, Li Y . Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue. Sci Rep. 2013; 3:2767. PMC: 3783882. DOI: 10.1038/srep02767. View

Pipatpiboon N, Pratchayasakul W, Chattipakorn N, Chattipakorn S . PPARγ agonist improves neuronal insulin receptor function in hippocampus and brain mitochondria function in rats with insulin resistance induced by long term high-fat diets. Endocrinology. 2011; 153(1):329-38. DOI: 10.1210/en.2011-1502. View

Cong W, Ling J, Tian H, Ling R, Wang Y, Huang B . Proteomic study on the protective mechanism of fibroblast growth factor 21 to ischemia-reperfusion injury. Can J Physiol Pharmacol. 2013; 91(11):973-84. DOI: 10.1139/cjpp-2012-0441. View

10.

Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S . Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One. 2011; 5(12):e15534. PMC: 3012070. DOI: 10.1371/journal.pone.0015534. View

11.

Tedgui A, Mallat Z . Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006; 86(2):515-81. DOI: 10.1152/physrev.00024.2005. View

12.

Wu X, Qi Y, Chang J, Lu W, Zhang J, Wang S . Possible role of fibroblast growth factor 21 on atherosclerosis via amelioration of endoplasmic reticulum stress-mediated apoptosis in apoE(-/-) mice. Heart Vessels. 2014; 30(5):657-68. DOI: 10.1007/s00380-014-0557-9. View

13.

Kusminski C, Bickel P, Scherer P . Targeting adipose tissue in the treatment of obesity-associated diabetes. Nat Rev Drug Discov. 2016; 15(9):639-660. DOI: 10.1038/nrd.2016.75. View

14.

Fisher F, Chui P, Antonellis P, Bina H, Kharitonenkov A, Flier J . Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010; 59(11):2781-9. PMC: 2963536. DOI: 10.2337/db10-0193. View

15.

Kushnir A, Santulli G, Reiken S, Coromilas E, Godfrey S, Brunjes D . Ryanodine Receptor Calcium Leak in Circulating B-Lymphocytes as a Biomarker in Heart Failure. Circulation. 2018; 138(11):1144-1154. PMC: 6162180. DOI: 10.1161/CIRCULATIONAHA.117.032703. View

16.

Nakamura K, Fuster J, Walsh K . Adipokines: a link between obesity and cardiovascular disease. J Cardiol. 2013; 63(4):250-9. PMC: 3989503. DOI: 10.1016/j.jjcc.2013.11.006. View

17.

Pratchayasakul W, Kerdphoo S, Petsophonsakul P, Pongchaidecha A, Chattipakorn N, Chattipakorn S . Effects of high-fat diet on insulin receptor function in rat hippocampus and the level of neuronal corticosterone. Life Sci. 2011; 88(13-14):619-27. DOI: 10.1016/j.lfs.2011.02.003. View

18.

Li J, Wang N, Khoso M, Shen C, Guo M, Pang X . FGF-21 Elevated IL-10 Production to Correct LPS-Induced Inflammation. Inflammation. 2018; 41(3):751-759. DOI: 10.1007/s10753-018-0729-3. View

19.

Shetelig C, Limalanathan S, Hoffmann P, Seljeflot I, Gran J, Eritsland J . Association of IL-8 With Infarct Size and Clinical Outcomes in Patients With STEMI. J Am Coll Cardiol. 2018; 72(2):187-198. DOI: 10.1016/j.jacc.2018.04.053. View

20.

Markan K . Defining "FGF21 Resistance" during obesity: Controversy, criteria and unresolved questions. F1000Res. 2018; 7:289. PMC: 6020717. DOI: 10.12688/f1000research.14117.1. View